WUXAY - Week In Review: Under Pressure From U.S. Congress WuXi AppTec Resigns From BIO
2024-03-17 03:20:00 ET
Summary
- BIO, the global lobbying organization for biotechnology firms, forced WuXi AppTec to leave the group due to pressure from the US Congress.
- Germany’s Boehringer Ingelheim acquired an option to license drug candidates that treat all symptoms of schizophrenia from Sosei Heptares of Japan in an agreement worth up to $822M.
- Jiangsu Hansoh Pharma extended its partnership with Zhuhai Biotheus, acquiring global rights to Zuhai’s proprietary anti-EGFR/cMet bispecific antibody in a $700 million agreement.
- PegBio, a Suzhou biotech, filed for a Hong Kong IPO to support commercialization of its long-acting pegylated GLP-1 receptor agonist for type 2 diabetes and obesity.